Kristy M. Ainslie
 | This article has multiple issues. Please help improve it or discuss these issues on the talk page. (Learn how and when to remove these template messages)
|
Kristy M. Ainslie | |
|---|---|
| Citizenship | USA |
| Alma mater | Pennsylvania State University, Michigan State University |
| Scientific career | |
| Fields | Engineering, Pharmacy |
| Doctoral advisor | John Tarbell, Michael Pishko |
| Website | ainslielab |
Kristy M. Ainslie is a Fred Eshelman Distinguished Professor in pharmaceutical science at University of North Carolina at Chapel Hill in the Eshelman School of Pharmacy and chair of the Division of Pharmacoengineering and Molecular Pharmaceutics. She is also joint in the UNC School of Medicine Department of Microbiology and Immunology and affiliated faculty in the UNC/NC State joint Biomedical Engineering department. Additionally, she is part of UNC's Biological and Biomedical Sciences Program (BBSP).
Background
[edit]Ainslie completed her Bachelor of Science in chemical engineering from Michigan State University in 1999. After working as an environmental engineer at Malcolm Pirnie, she began graduate school at Penn State as a fellow in the Huck Institutes of the Life Science. In 2003, she completed her Master of Science in chemical engineering under John Tarbell, focusing on shear stress modulation of vascular smooth muscle cell contraction.[1][2][3][4][5] Two years later in 2005, she completed her PhD in Chemical engineering under Micheal Pishko, focusing on protein adhesion and cell responses to nanomaterials.[6][7][8][9][10] After a brief post doc at the microcantilever start-up Protiveris, she worked with Lloyd Whitman at the United States Naval Research Laboratory.[11] In 2006, she began a post doc at University of San Francisco in the department of bioengineering and therapeutic sciences under the direction of Tejal Desai. The focus of Ainslie's research at UCSF was on microfabricated oral drug delivery[12][13] carriers and immune responses to planar nanomaterials.[14][15]
Ainslie began her career as a tenure-track assistant professor at Ohio State University in the school of pharmacy in the division of pharmaceutics and pharmaceutical chemistry. In 2014, Ainslie moved to the University of North Carolina at Chapel Hill and the UNC Eshelman School of Pharmacy division of pharmacoengineering and molecular pharmaceutics as an associate professor.
Career
[edit]Ainslie has several areas of focus for her lab:
- Advancement of acetalated dextran: Establishment of an ethanol producing version of acetalated dextran,[16] in comparison to the methanol producing version first reported by Jean Fréchet.[17][18] Exploiting the unique degradation rates of acetalated dextran, the Ainslie Lab was the first to show that fine tuning of antigen and adjuvant release can be used to optimize microparticulate vaccines.[19]
- Antigen specific immune tolerance: One of the first to apply microparticles for autoimmune therapeutic vaccines,[20] using acetalated dextran to suppress disease related inflammation
- Host-directed therapeutics: First identifying OSU-03012 antiparasitic activity against Leishmania donovani.[21][22] To improve the delivery of this compound, since it has a narrow therapeutic window, the Ainslie lab encapsulated it in acetalated dextran microparticles and also applied the formulation for Salmonella enterica and Francisella tularensis infection.[23][24]
- Electrospray for vaccines: Reported the first use of electrospray for formation of protein based microparticle vaccines made of acetalated dextran.[25] The application of electrospray was then expanded to encapsulate the hydrophillic STING agonist cGAMP.[26]
- Electrospun acetalated dextran nanofibers: Used for interstitial delivery of chemotherapeutics for glioblastoma.[27]
References
[edit]- ^ Sharma, Ritu; Yellowley, Claire; Civelek, Mete; Ainslie, Kristy; Hodgson, Louis; Tarbell, John; Donahue, Hennry (2002). "Intracellular Calcium Changes in Rat Aortic Smooth Muscle Cells in Response to Fluid Flow". Annals of Biomedical Engineering. 30 (3): 371–8. doi:10.1114/1.1470179. PMC 4472337. PMID 12051621.
- ^ Civelek, Mete; Ainslie, Kristy; Garanich, Jeffery; Tarbell, John (2002). "Smooth muscle cells contract in response to fluid flow via a Ca2+-independent signaling mechanism". J Appl Physiol. 93 (6): 1907–17. CiteSeerX 10.1.1.490.2931. doi:10.1152/japplphysiol.00988.2001. PMID 12391063. S2CID 6734621.
- ^ Florian, Jeffery; Kosky, Jason; Ainslie, Kristy; Pang, Zhang; Dull, Randall; Tarbell, John (2003). "Heparan sulfate proteoglycan is a mechanosensor on endothelial cells". Circulation. 93 (10): e136–42. doi:10.1161/01.RES.0000101744.47866.D5. PMID 14563712.
- ^ Ainslie, Kristy; Shi, Z; Garanich, Jeffery; Tarbell, John (2004). "Rat aortic smooth muscle cells contract in response to serum and its components in a calcium independent manner". Annals of Biomedical Engineering. 32 (12): 1667–75. doi:10.1007/s10439-004-7820-7. PMID 15675680. S2CID 12752100.
- ^ Ainslie, Kristy; Garanich, Jeffery; Dull, Randall; Tarbell, John (2005). "Vascular smooth muscle cell glycocalyx influences shear stress-mediated contractile response". J Appl Physiol. 98 (1): 242–9. doi:10.1152/japplphysiol.01006.2003. PMID 15322072. S2CID 19602119.
- ^ Dyer, Maureen; Ainslie, Kristy; Pishko, Micheal (2007). "Protein adhesion on silicon-supported hyperbranched poly(ethylene glycol) and poly(allylamine) thin films". Langmuir. 23 (13): 7018–23. doi:10.1021/la7004997. PMID 17506587.
- ^ Ainslie, Kristy; Sharma, Gurav; Dyer, Maureen; Grimes, Craig; Pishko, Micheal (2005). "Attenuation of protein adsorption on static and oscillating magnetostrictive nanowires". Nano Letters. 5 (9): 1852–6. Bibcode:2005NanoL...5.1852A. doi:10.1021/nl051117u. PMID 16159237.
- ^ Ainslie, Kristy; Bachelder, Eric; Borka, Sachin; Zahr, Alisar; Sen, Ayusman; Badding, John; Pishko, Micheal (2007). "Cell adhesion on nanofibrous polytetrafluoroethylene (nPTFE)". Langmuir. 23 (2): 747–54. doi:10.1021/la060948s. PMID 17209629.
- ^ Kristy, Ainslie; Bachelder, Eric; Sharma, Gurav; Grimes, Craig; Pishko, Micheal (2009). "Macrophage cell adhesion and inflammation cytokines on magnetostrictive nanowires". Nanotoxicology. 1 (4): 279. doi:10.1080/17435390701781142. S2CID 85936269.
- ^ Bachelder, Eric; Ainslie, Kristy; Pishko, Micheal (2005). "Utilizing a quartz crystal microbalance for quantifying CD4+ T cell counts". Sensor Letters. 3 (3): 211. doi:10.1166/sl.2005.029.
- ^ Stine, Rory; Cole, Christina; Ainslie, Kristy; Mulvaney, Shawn; Whitman, Lloyd (2007). "Formation of primary amines on silicon nitride surfaces: a direct, plasma-based pathway to functionalization". Langmuir. 23 (8): 4400–4. doi:10.1021/la0635653. PMID 17323989.
- ^ Ainslie, Kristy; Kraning, Casey; Desai, Tejal (2008). "Microfabrication of an asymmetric, multi-layered microdevice for controlled release of orally delivered therapeutics". Lab Chip. 8 (7): 1042–7. doi:10.1039/b800604k. PMC 2969854. PMID 18584077.
- ^ Ainslie, Kristy; Lowe, Rachel; Beaudette, Tristan; Petty, Lamar; Bachelder, Eric; Desai, Tejal (2009). "Microfabricated devices for enhanced bioadhesive drug delivery: attachment to and small-molecule release through a cell monolayer under flow". Small. 5 (24): 2857–63. doi:10.1002/smll.200901254. PMID 19787677.
- ^ Kristy, Ainslie; Tao, Sarah; Popat, Ketul; Daniels, Hugh; Hardev, Veeral; Grimes, Craig; Desai, Tejal (2009). "In vitro inflammatory response of nanostructured titania, silicon oxide, and polycaprolactone". J Biomed Mater Res A. 91 (3): 647–55. doi:10.1002/jbm.a.32262. PMID 18988278.
- ^ Ainslie, Kristy; Tao, Sarah; Popat, Ketul; Desai, Tejal (2008). "In vitro immunogenicity of silicon-based micro- and nanostructured surfaces". ACS Nano. 2 (5): 1076–84. doi:10.1021/nn800071k. PMID 19206506.
- ^ Kauffman, KJ; Do, C; Sharma, S; Gallovic, MD; Bachelder, EM; Ainslie, KM (Aug 2012). "Synthesis and characterization of acetalated dextran polymer and microparticles with ethanol as a degradation product". ACS Appl Mater Interfaces. 4 (8): 4149–55. doi:10.1021/am3008888. hdl:1811/86186. PMID 22833690.
- ^ Bachelder, EM; Beaudette, TT; Broaders, KE; Dashe, J; Fréchet, JM (Aug 2008). "Acetal-derivatized dextran: an acid-responsive biodegradable material for therapeutic applications". Journal of the American Chemical Society. 130 (32): 10494–5. doi:10.1021/ja803947s. PMC 2673804. PMID 18630909.
- ^ Frechet, JM; Bachelder, EM; Beaudette, TT; Broaders, KE. "Acid-Degradable and Bioerodible Modified Polyhydroxylated Materials". Google Patent. Archived from the original on 2017-08-07. Retrieved 2018-06-26.
- ^ Chen, Naihan; Johnson, Monica; Collier, Micheal; Gallovic, Matthew; Johnson, Monica; Ainslie, Kristy (2018). "Tunable degradation of acetalated dextran microparticles enables controlled vaccine adjuvant and antigen delivery to modulate adaptive immune responses". Journal of Controlled Release. 273: 147–159. doi:10.1016/j.jconrel.2018.01.027. PMC 5835201. PMID 29407676.
- ^ Ainslie, Kristy. "Encapsulated Active Vitamin D Vaccine for the Treatment of Multiple Sclerosis". Grantome. Archived from the original on 15 October 2019. Retrieved 15 October 2019.
- ^ Collier, MA; Peine, KJ; Gautum, S; Oghumu, S; Varikuti, S; Borteh, H; Papenfuss, TL; Satoskar, AR; Bachelder, EM; Ainslie, KM (Feb 29, 2016). "Host-mediated Leishmania donovani treatment using AR-12 encapsulated in acetalated dextran microparticles". International Journal of Pharmaceutics. 499 (1–2): 186–94. doi:10.1016/j.ijpharm.2016.01.004. PMC 5730989. PMID 26768723.
- ^ Ainslie; et al. "COMPOSITIONS AND METHODS FOR INHIBITING LEISHMANIA". Free Patents Online. Archived from the original on 2018-06-27. Retrieved 2018-06-26.
- ^ Hoang, KV; Borteh, HM; Rajaram, MV; Peine, KJ; Curry, H; Collier, MA; Homsy, ML; Bachelder, EM; Gunn, JS; Schlesinger, LS; Ainslie, KM (Dec 2014). "Acetalated dextran encapsulated AR-12 as a host-directed therapy to control Salmonella infection". Int J Pharm. 477 (1–2): 334–43. doi:10.1016/j.ijpharm.2014.10.022. PMC 4267924. PMID 25447826.
- ^ Hoang, KV; Curry, H; Collier, MA; Borteh, H; Bachelder, EM; Schlesinger, LS; Gunn, JS; Ainslie, KM (Mar 25, 2016). "Needle-Free Delivery of Acetalated Dextran-Encapsulated AR-12 Protects Mice from Francisella tularensis Lethal Challenge". Antimicrob Agents Chemother. 60 (4): 2052–62. doi:10.1128/AAC.02228-15. PMC 4808193. PMID 26787696.
- ^ Gallovic, Matthew; Schully, Kevin; Bell, Matthew; Elberson, Margret; Palmer, John; Darko, Christen; Bachelder, Eric; Keane-Myers, Andrea; Ainslie, Kristy (2016). "Acetalated Dextran Microparticulate Vaccine Formulated via Coaxial Electrospray Preserves Toxin Neutralization and Enhances Murine Survival Following Inhalational Bacillus Anthracis Exposure". Advanced Healthcare Materials. 5 (20): 2617–2627. doi:10.1002/adhm.201600642. PMID 27594343. S2CID 42823279.
- ^ Junkins, Robert; Gallovic, Matthew; Johnson, Brandon; Collier, Micheal; Watkins-Schulz, Rebekah; Cheng, Ning; David, Clement; McGee, Charles; Sempowski, Greg; Shterev, Ivo; McKinnon, Karen; Bachelder, Eric; Ainslie, Kristy; Ting, Jenny (2018). "A robust microparticle platform for a STING-targeted adjuvant that enhances both humoral and cellular immunity during vaccination". J Control Release. 270: 1–13. doi:10.1016/j.jconrel.2017.11.030. PMC 5808851. PMID 29170142.
- ^ Graham-Gurysh, Elizabeth; Moore, Kathryn; Satterlee, Andrew; Sheetz, Kevin; Lin; Bachelder, Eric; Miller, C. Ryan; Hingtgen, Shawn; Ainslie, Kristy (2018). "Sustained Delivery of Doxorubicin via Acetalated Dextran Scaffold Prevents Glioblastoma Recurrence after Surgical Resection". Mol Pharm. 15 (3): 1309–1318. doi:10.1021/acs.molpharmaceut.7b01114. PMC 5999333. PMID 29342360.
External links
[edit]- Kristy M. Ainslie publications indexed by Google Scholar
| Authority control databases: Academics |
|---|
